full
border
#666666
https://www.arboretumvc.com/wp/wp-content/themes/zap-installable/
https://www.arboretumvc.com/wp/
#ffffff
style1

Pear Therapeutics News

17
Jan

Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.
Link

15
Sep

Pear Therapeutics, the leader in a new era of prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Pear’s De Novo request, allowing the company to market reSET® for the treatment of patients with substance use disorder (SUD) under a new class of treatment. This is the first time that the FDA has cleared a Prescription Digital Therapeutic with claims to improve clinical outcomes in a disease.
Link

03
Feb

Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulationsTM, announced today that it has successfully closed on a $20M equity financing. 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners led the round, with participation from Bridge Builders Collaborative and several additional investors.

Link

Pear Therapeutics aims to use drugs with an app to help addicts kick the habit ~ The Boston Business Journal Article

Link

1
1
scrollauto
Loading posts...
link_magnifier
#ffffff
on
loading
off